Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 14Lymphoma, Large B-Cell, Diffuse 14Lymphoma, Non-Hodgkin 11Leukemia, Myeloid, Acute 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Leukemia, Lymphocytic, Chronic, B-Cell 9Lymphoma, Mantle-Cell 8Lymphoma, Follicular 8Lymphoma, B-Cell 7Glioblastoma 7Hodgkin Disease 6Burkitt Lymphoma 6Lymphoma 5Recurrence 4Prostatic Neoplasms 4Lymphoma, B-Cell, Marginal Zone 4Hematologic Neoplasms 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Sarcoma 3Ovarian Neoplasms 3Myelodysplastic Syndromes 3Melanoma 3Lymphoma, Large-Cell, Anaplastic 3Leukemia 3Glioma 3Astrocytoma 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Sarcoma, Synovial 2

Interventions

PROSTVAC 1Nivolumab 1Leukapheresis 1Ipilimumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Metastatic Hormone-Sensitive Prostate Cancer × Leukapheresis × Clear all
NCT03532217 2022-08-05

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Washington University School of Medicine

Phase 1 Completed
19 enrolled
Genitourinary

Metastatic Hormone-Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡